Kolexia
Boyer-Darrigrand Nathalie Gastro-entérologie
Boyer-Darrigrand Nathalie
Gastro-entérologie
Hôpital Beaujon
Clichy, France
138 Activités
699 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hépatite Hépatite B Hépatite chronique Hépatite C Hépatite C chronique Hépatite B chronique Fibrose Hépatite D Hépatite A

Collaborateurs

Voir plus
Marcellin Patrick
Marcellin Patrick
Hôpital Beaujon, Clichy, France
Asselah Tarik
Asselah Tarik
Hôpital Beaujon, Clichy, France
Castelnau-Marchand Corinne
Castelnau-Marchand Corinne
Hôpital Beaujon, Clichy, France
Bedossa Pierre
Bedossa Pierre
Hôpital Beaujon, Clichy, France

Industries

Voir plus
Gilead
10 collaboration(s)
Dernière en 2023
Abbvie
6 collaboration(s)
Dernière en 2023
agence européenne informatique
6 collaboration(s)
Dernière en 2021
MSD
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD): A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta
Essai Clinique (Gilead)   12 septembre 2023
D-LIVR: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Essai Clinique (Eiger Biopharmaceuticals)   13 avril 2023
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD): A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta
Essai Clinique (Gilead)   24 mars 2023
LOWR-1: An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)
Essai Clinique (Eiger Biopharmaceuticals)   03 novembre 2022
Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.)   16 septembre 2022
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Essai Clinique (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK))   06 décembre 2021
New therapies for hepatitis delta virus infection.
Liver international : official journal of the International Association for the Study of the Liver   25 juin 2021
New therapies for hepatitis delta virus infection
Proceedings of the 14th Paris Hepatology Conference. International Conference on the Management of Liver Diseases, 8‐10 March 2021, Paris, France   21 juin 2021
Future treatments for hepatitis delta virus infection.
Liver international : official journal of the International Association for the Study of the Liver   21 juin 2021
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
Liver international : official journal of the International Association for the Study of the Liver   08 juin 2021